MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
04 November 2024 02:30PM

EQS-News: MEDICLIN increases consolidated sales and operating result - Management Board confirms annual forecast for 2024

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2022023

EQS-News: MEDICLIN AG / Key word(s): 9 Month figures/Miscellaneous
MEDICLIN increases consolidated sales and operating result - Management Board confirms annual forecast for 2024

04.11.2024 / 14:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 04 November 2024
MEDICLIN increases consolidated sales and operating result - Management Board confirms annual forecast for 2024
  • MEDICLIN increases consolidated sales for 9M 2024 by 2.0% to EUR 558.2 million
  • Group EBIT of EUR 34.5 million higher than in the same period of the
    previous year (9M 2023: EUR 29.4 million)
  • Occupancy rate up on previous year at 86.0 (9M 2023: 84,4%)
  • Hospital reform expected at the turn of the year
  • The Executive Board confirms the forecast for the year

Offenburg, 04 November 2024: In the first nine months of 2024, MEDICLIN Aktiengesellschaft (MEDICLIN) generated consolidated sales of EUR 558.2 million. This is EUR 11.1 million or 2.0% more than in the first nine months of 2023. The consolidated operating result improved by EUR 5.1 million to EUR 34.4 million compared to the same period of the previous year. A positive business performance in the third quarter and a stable capacity utilisation rate of 86.0% (9M 2023: 84.4%) allow the Executive Board to confirm the annual forecast. For the current financial year, a decline in sales at the upper end of the forecast of -2.0% to 0.0% is expected. The consolidated operating result is now also expected to be at the upper end of the range of EUR 33.0 million to EUR 39.0 million last specified in the first half of the year.

Sales and earnings performance of the segments

In the post-acute segment, sales increased by 7.2% to EUR 361.2 million (9M 2023: EUR 337.0 million). At EUR 38.0 million, the segment operating result was EUR 2.9 million higher than in the same period of the previous year (9M 2023: EUR 35.1 million). The cost of materials ratio rose by 0.3 percentage points to 20.4% (9M 2023: 20.1%). At EUR 73.8 million, the absolute cost of materials was 9.1% higher than in the previous year (9M 2023: EUR 67.6 million). Personnel expenses increased by EUR 8.1 million or 4.5% to EUR 187.4 million compared to the first half of the previous year. The personnel expenses ratio fell to 51.9% (9M 2023: 53.2%).

The acute segment reported a decline in segment sales of EUR 16.3 million or 8.5%. The segment operating result totalled EUR -3.8 million after EUR -5.4 million in the third quarter of 2023. The cost of materials fell by 12.8% to EUR 50.0 million (9M 2023: EUR 57.3 million). The cost of materials ratio fell slightly to 28.5 % (9M 2023: 29.9%). Personnel expenses totalled EUR 106.1 million and were therefore 8.6% lower than in the first nine months of 2023 (9M 2023: EUR 116.1 million). The personnel expenses ratio remained almost unchanged at 60.4% after 60.5% in the same period of the previous year.

Sales in the Other Activities segment totalled EUR 21.5 million was 17.5% higher than the previous year's figure, i.e. EUR 3.2 million. The nursing care business division contributed EUR 17.5 million to this figure, which corresponds to an increase of 11.3% compared to the previous year (9M 2023: EUR 15.8 million). At EUR 0.3 million, the segment operating result was up on the previous year's result of EUR
-0.3 million.

Outlook - positive business performance in the third quarter of 2024

"As in previous years, the third quarter is once again the strongest of the current year. Group sales increased by EUR 7.9 million year-on-year to EUR 190.2 million. Profitability for the quarter was also positive with an EBIT margin of 11.8%. We are in a good financial position and confirm the annual forecasts for sales and consolidated operating profit at the upper end in each case due to the positive business develop-ment", reports Tino Fritz, CFO of MEDICLIN.

Hospital reform expected at the turn of the year

"The hospital reform expected at the turn of the year has not taken rehabilitation into account. We are convinced that the elimination of hospital beds in the acute sector will not lead to fewer, but to more and earlier rehabilitation services. With MEDICLIN HOME, DIRECT and CAMPUS, we set out early on to face up to the developments in the healthcare market and take advantage of the opportunities offered by the outpati-ent and digitalisation of rehabilitation," says Dr Joachim Ramming, CEO of MEDICLIN.

Thomas Piefke, COO of MEDICLIN, adds: "On 11 October, we opened outpatient orthopaedic rehabilitation at the Staufenburg Klinik in Durbach - as part of the MEDICLIN DIRECT range of services. With the expansion of this service, we are supplementing the existing services for rehabilitation in the areas of cancer, diabetes and obesity and are thus responding to the increasing demand for outpatient orthopaedic therapies. We are thus successfully driving forward outpatientisation at MEDICLIN and consistently implementing our strategy."

The interim report as at 30 September 2024 is available from today at www.mediclin.de in German and English.

For further information:

MEDICLIN Aktiengesellschaft
Okenstrasse 27
77652 Offenburg

Investor Relations
Ender Gülcan
Phone: 0781/488-326
ender.guelcan@mediclin.de


Public Relations
Dr Janina Lossen
Phone: 0781/488-180
janina.lossen@mediclin.de

www.mediclin.de


About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group

 


04.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2022023

 
End of News EQS News Service

2022023  04.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2022023&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 645,11 673,09 659,86 673,14 704,70 730,07 759,00
EBITDA1,2 37,35 93,58 77,50 85,22 90,92 98,73 127,00
EBITDA-Margin3 5,79 13,90 11,75 12,66 12,90 13,52 16,73
EBIT1,4 15,06 22,41 0,15 11,56 19,52 12,72 42,00
EBIT-Margin5 2,33 3,33 0,02 1,72 2,77 1,74 5,53
Net Profit (Loss)1 7,76 9,68 -0,04 1,49 9,72 -10,72 18,00
Net-Margin6 1,20 1,44 -0,01 0,22 1,38 -1,47 2,37
Cashflow1,7 29,77 69,59 118,69 81,97 34,64 78,00 0,00
Earnings per share8 0,16 0,20 -0,19 0,03 0,20 -0,23 0,38
Dividend per share8 0,05 0,05 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: PricewaterhouseCoopers

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Mediclin
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
659510 DE0006595101 AG 116,85 Mio € 06.12.2000 Halten 8FW9FWGV+63
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
9,46 19,13 0,49 18,50 0,60 1,50 0,16
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
04.06.2025 02.05.2025 31.07.2025 04.11.2024 28.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+1,65%
2,46 €
ATH 15,02 €
+0,20% -3,61% -10,22% -7,52% -77,64%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL